Additional file 1 of TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro

Additional file 1: Table S1-S11. Table S1. Strengthening the Reporting of Observational Studies in Epidemiology using Mendelian Randomization (STROBE-MR) checklist. Table S2. The details of eQTL used in the study. Table S3. Primers used in qPCR experiments. Table S4. Mendelian Randomization Analysis Results for Blood Gene Expression and ALS Outcomes of SNPs under different criteria. Table S5. Mendelian Randomization Analysis Results for Brain Gene Expression and ALS Outcomes of SNPs under different criteria. Table S6. Mendelian Randomization Analysis Results for Spinal cord Gene Expression and ALS Outcomes of SNPs under different criteria. Table S7. Druggable genes associated with ALS. Table S8. Sensitivity analyses by MR-Egger and weighted median methods. Table S9. The results of colocalization analysis. Table S10. Wald ratio approach supporting the expression of druggable genes significantly associated with ALS risk. Table S11. The phenome-wide MR results of blood TBK1 in IVW or Wald ratio method.